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ABSTRACT
Background: Thrombomodulin treatment modulates the properties of dendritic cells (DCs) converting them
from immunogenic to tolerogenic and inducing its own expression on DCs. Thrombomodulin binds to the in-
flammatory mediator, high mobility group protein B1 (HMGB1), antagonizing signalling through its receptor, re-
ceptor for advanced glycation end products (RAGE).
Methods: To test if soluble thrombomodulin could antagonize HMGB1 signaling via RAGE on DCs. DCs were
prepared from mouse bone marrow cells or human monocytes. In some experiments dendritic cells were sorted
into thrombomodulin+ and thrombomodulin− populations. Expression of surface maturation markers was deter-
mined by flow cytometry following treatment with thrombomodulin in the presence or absence of HMGB1.
Results: Thrombomodulin+ dendritic cells secrete less HMGB1 into the medium. HMGB1 reduces the effects
of thrombomodulin on expression of DC maturation markers. Treatment with thrombomodulin reduces the ex-
pression of maturation markers such as CD80 and CD86 and increases the expression of thrombomodulin on
the DC surface. Treatment of DCs with neutralizing anti-HMGB1 antibody acted synergistically with thrombo-
modulin in increasing thrombomodulin expression on DCs. Treatment with thrombomodulin can still reduce the
expression of surface markers on DCs derived from mice that are deficient in RAGE showing that thrombo-
modulin can affect DCs by an alternative mechanism.
Conclusions: The results of this study show that thrombomodulin modulates DCs both by antagonizing the
interaction of HMGB1 with RAGE and by an independent mechanism.
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ABBREVIATIONS
aPC, activated protein C; DC, dendritic cell; EGF, epidermal growth factor; HMGB1, high mobility group protein
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thrombomodulin; TAFI, Thrombin Activatable Fibrinolysis Inhibitor; TM, thrombomodulin.
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INTRODUCTION
Thrombomodulin (TM), which is also known as feto-
modulin, CD141 or blood dendritic cell antigen
(BDCA)-3, is a cell surface protein that binds throm-
bin, the key effector enzyme of the coagulation cas-
cade, converting it from a pro-coagulant to an anti-
coagulant and anti-fibrinolytic enzyme.1,2 Thrombin
bound to TM is inhibited from cleaving fibrinogen,
protease-activated receptor (PAR)-1 and other pro-
coagulant substrates, but activates protein C (PC) to
the anti-coagulant and anti-inflammatory activated
protein C (aPC), and thrombin-activatable fibrinolysis
inhibitor (TAFI, pro-carboxypeptidase B2) to the anti-
fibrinolytic and anti-inflammatory activated TAFI
(TAFIa).3,4 In addition, TM exhibits anti-inflamma-
tory properties that do not involve thrombin.5,6
TM possesses discrete domains that have different
functions, including a N-terminal C-type lectin do-
main, 6 copies of the Epidermal Growth Factor
(EGF) motif, an O-linked glycosylation domain, a
transmembrane domain and a cytoplasmic domain.2,7
Thrombin binds to EGF motifs 5 + 6, while EGF 4 is
required in addition to EGFs 5 + 6 for PC activation
and EGFs 3 - 6 are necessary for TAFI activation. The
N-terminal lectin domain binds a sugar moiety, Le-
wisy,8 as well as high mobility group B1 (HMGB1)
protein.9 HMGB1 is a chromosomal protein that
when released into the extracellular matrix acts as a
defensin, inducing cell signalling by binding to its re-
ceptor, the receptor for advanced glycation end-
products (RAGE)10 that signals in conjunction with
Toll receptors.11,12 In addition, when HMGB1 is
bound to TM, the rate of its cleavage by thrombin is
accelerated.13 The lectin domain of TM is a functional
antagonist of HMGB1 signalling via RAGE.9
Dendritic cells (DCs) are professional antigen pre-
senting cells that phagocytose antigens in peripheral
tissues and migrate to lymph nodes where they play a
role in the generation of antigen-specific effector T
cells.14,15 Coagulation cascade proteins may affect im-
munity by modulating the function of DCs.16-20 A re-
cent study has demonstrated that TM modulates the
properties of DCs.21 Adoptive transfer of TM-treated
DCs inhibits the development of allergen-induced
bronchial asthma, suggesting that TM induces tolero-
genic DCs. In addition, TM treated DCs were found
to have lower levels of maturation markers as well as
increased expression of TM on their cell surface.21
On the other hand, HMGB1 has been reported to in-
duce immunogenic DCs by activating the cells
through a RAGE dependent mechanism.22 In this
study we hypothesized that TM induces tolerogenic
DCs by antagonizing HMGB1. The results of this in-
vestigation showed that TM modulates DCs both via
HMGB1 antagonism and by an alternative mecha-
nism.
METHODS
MATERIALS
Soluble recombinant human TM (ART123; rhTM)
was supplied by Asahi Kasei Corporation (Tokyo, Ja-
pan) and was clinical grade material approved for use
in Japan and does not contain LPS. HMGB1 and anti-
HMGB1 IgY antibody were purchased from Shino-
test Corporation (Kanagawa, Japan). RPMI 1640 me-
dium was from Sigma (St Louis, MO, USA). Fetal bo-
vine serum (FBS) was from BioWhittaker (Walkers-
ville, MD, USA).
MICE
Mie University Committee on animal investigation ap-
proved the experimental protocols, and the experi-
ments were performed according to the guidelines
for animal experiments of the National Institute of
Health. 9-week-old, female BALBc and C57BL6
mice that weighed 17-18 g were purchased from Ja-
pan SLC (Shizuoka, Japan) and housed in the animal
facility of Mie University. Mice were maintained on a
constant 12-hour light12-hour dark cycle in a
temperature- and humidity-controlled room and were
given ad libitum access to food and water. Age-
matched, female RAGE deficient mice were used in
some experiments. They had been backcrossed for
more than 10 generations onto a C57Bl6 back-
ground and have been described previously.23
MOUSE DC GENERATION AND MATURATION
Bone marrow-derived DCs were prepared as de-
scribed.24 The bone marrow cells were resuspended
at 5 × 105 cellsml in RPMI 1640 with 10% heat-
inactivated FBS containing 50 ngml murine granulo-
cyte-macrophage colony-stimulating factor (GM-CSF)
and 3 mlwell in 6-well tissue culture plates was cul-
tured for 6 days. In some experiments the FBS was
depleted of HMGB1 by passing it over a column of
anti-HMGB1 IgY antibody. rhTM was added on day 4
at a final concentration of 200 nM as was HMGB1 at 2
μgml. TM+ and TM− DCs were separated on day 6
using a rat anti-mouse TM mAb (R&D, Minneapolis,
MN, USA) and anti-rat IgG magnetic microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany). The
purity of both the TM+ and TM− DC preparations was
>93% determined by flow cytometry after staining
with anti-TM antibody.
HUMAN DC GENERATION
The study protocol was approved by the Mie Univer-
sity Hospital Institutional Review Board and the in-
vestigation was carried out following the Helsinki
Declaration. Informed consent was obtained from all
participants before blood sampling. Peripheral blood
cells were isolated by Ficoll-Paque (GE Health Care
Bioscience, Uppsala, Sweden) and then monocytes
were purified from peripheral blood mononuclear
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Fig.　1　TM treatment of DCs reduces release of HMGB1. 
The levels of HMGB1 were determined in conditioned medi-
um. A high concentration of HMGB1 was present in condi-
tioned medium from DCs derived from BALB/c mice, which 
is reduced in medium from rhTM-treated BMDCs. Sorted 
TM+ DCs release less HMGB1 than TM− DCs. The mean of 
three independent experiments is shown. Error bars indicate 
s.d.
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cells using a two-hour adherence step on plastic
dishes. Adherent cells (>95% monocytes as deter-
mined by flow cytometric analysis) were cultured at 5
× 105 cellsml in RPMI 1640 with 10% FBS containing
50 ngml human GM-CSF (Peprotech, Rock Hill, NJ,
USA) and 50 ngml human IL-4 (Peprotech) at 3 ml
well in 6-well tissue culture plates (Becton Dickinson
Labware, Franklin Lakes, NJ, USA). rhTM was added
on day 4 to a final concentration of 200 nM as was
HMGB1 to a final concentration of 2 μgml.
FLOW CYTOMETRY
Human DCs were analysed by FACScan flow cytome-
ter on a CellQuest software (Becton Dickinson, San
Jose, CA, USA) following staining with PE-Cy5-
labeled anti human CD11c (Biolegend, San Diego,
CA, USA) and phycoerytrin (PE)-labeled anti-human
CD86 (BD Bioscience, San Jose, CA, USA) or PE-
labeled anti-HLA-DR (BD Bioscience), and fluo-
rescein isothiocynate (FITC) -labeled anti-TM
(Miltenyi Biotec) antibodies. CD11c+ SSClow cells
were gated as DCs. Mouse DCs were analysed
following staining with PE-Cy5-labeled anti-mouse
CD11c (BD Bioscience) and FITC-labeled rat anti-
mouse TM that does not cross react with human TM
(R&D Systems).
BIOCHEMICAL ASSAYS
The concentration of HMGB1 was determined by
ELISA using a commercially available kit (Shino-Test
Corporation) following the manufacturer’s instruc-
tions. The levels of both mouse and human tumor ne-
crosis factor-α (TNF-α) and interleukin-12 p70 (IL-12
p70) were determined by ELISAs obtained from R&D
systems.
STATISTICS
All data are expressed as the mean ± standard devia-
tion (s.d.). Comparison of two variables was by two
tailed Student’s t test. Where appropriate the statisti-
cal difference between three or more variables was
calculated by ANOVA with post hoc analysis using
Tukey’s test. Statistical analyses were carried out us-
ing StatView 4.1 (Abacus Concepts) for the Macin-
tosh. p < 0.05 was considered as statistically signifi-
cant.
RESULTS
HMGB1 IS LOWER IN MEDIUM FROM DCs
TREATED WITH TM
HMGB1 is a chromosomal protein that acts as a de-
fensin and is secreted during inflammation. It induces
a potent pro-inflammatory response following binding
to specific receptors, including the Receptor for Ad-
vanced Glycation End-Products (RAGE).9,25 The
lectin domain of TM has been shown to act as an an-
tagonist, interrupting its signalling via RAGE.9 Based
on these data we hypothesized that HMGB1 might
modulate the phenotype of DCs. We first showed that
the levels of HMGB1 present in heat inactivated FBS
by ELISA might be sufficient to affect the outcome of
these experiments. Affinity purification by passing
the FBS over a column of anti-HMGB1 IgY antibody
reduced the level of HMGB1 from 19.2 ± 6.9 ngml to
2.2 ± 0.6 ngml. Subsequent experiments were car-
ried out in FBS that had been depleted of HMGB1.
Treatment of in vitro differentiated unsorted DCs
derived from wild type BALBc mice with 200 nM
rhTM reduced the concentration of HMGB1 secreted
into the conditioned media (Fig. 1). When the DCs
were sorted into TM+ DCs and TM− DCs then the
TM+ DCs released less HMGB1 into the conditioned
media than TM− DCs confirming the data from un-
sorted DCs. This is consistent with the general
tolerogenic phenotype of DCs treated with TM or
sorted into TM+ DCs compared to the immunogenic
properties of control DCs or sorted TM− DCs.21
The reduction in HMGB1 in the medium is not due
to a decrease in mRNA as there was no difference in
mRNA levels analyzed by qPCR (data not shown).
This suggests that TM+ DCs produce the same
amount of HMGB1 as TM− DCs but that they release
less into the medium.
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Fig.　2　The presence of HMGB1 reduces TM expression on DCs. DCs from BALB/c mice were cultured in 
HMGB1-depleted medium with or without rhTM and the number of TM+ DCs was determined by fl ow cytometry, 
with isotype control in gray (A) and the percentage of TM+ DCs calculated (B). Representative results from three 
independent experiments are shown. Error bars indicate s.d. Data analyzed by ANOVA with post hoc Fisher’s 
predicted least signifi cant difference test.
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HMGB1 ANTAGONIZES THE EFFECT OF TM ON
DCs
The TM lectin domain may exert at least some of its
anti-inflammatory properties by binding to HMGB1,
thereby interfering with HMGB1 binding to RAGE.
As demonstrated by DCs from mice lacking the lectin
domain, the lectin domain of TM is essential for TM’s
ability to modulate DCs.21 So we investigated if addi-
tion of HMGB1 to the medium would reverse the ef-
fect of TM using the cell surface expression of TM as
a marker detected by flow cytometry. The monoclo-
nal antibody used to detect mouse TM is species spe-
cific, and so it is unlikely to detect residual rhTM that
was not removed in the washing steps. Differentiation
of bone marrow cells in serum depleted of HMBG1
leads to higher TM expression on DCs (Fig. 2) sug-
gesting that the presence of HMGB1 reduces TM ex-
pression. Addition of 200 nM rhTM increased the ex-
pression of TM on differentiating DCs, with the over-
all fraction of cells that express TM being highest in
cultures treated with rhTM in medium depleted of
HMGB1 (Fig. 2). The levels of HMGB1 produced by
control DCs or sorted TM− DCs are approximately
100 ngml (Fig. 1) or 4 nM so that the added rhTM is
in 25 fold molar excess.
ANTI-HMGB1 ANTIBODY POTENTIATES THE
EFFECT OF TM ON DCs
To demonstrate that the effect of HMGB1 was due to
the presence of HMGB1 in the medium as opposed
to concurrent changes in the DCs, differentiated DCs
were incubated in the presence of 2 μgml HMGB1.
Figure 3A shows that addition of 2 μgml HMGB1 to
the medium reduced the expression of TM on the
DC surface both in the absence as well as in the pres-
ence of 200 nM rhTM. Neutralizing HMGB1 pro-
duced by the cells with anti-HMGB1 IgY antibody
also leads to an increase in TM expression. To inves-
tigate further the effects of HMGB1 and rhTM treat-
ment, the level of the pro-inflammatory cytokine,
TNF-α, in the DC culture medium on day 6 was de-
termined by ELISA. Treatment with HMGB1 in-
creases TNF-α, levels, while rhTM addition reduces
it (Fig. 3B). If the effect of TM is solely due to its an-
tagonism of HMGB1 then when DCs are treated with
sufficient anti-HMGB1 antibody to bind all available
HMGB1, exogenous rhTM should not increase the
percentage of TM expressing DCs. The percentage
of TM+ DCs was increased by simultaneous treat-
ment with both rhTM and anti-HMGB1, however,
suggesting that TM can act both independently of
HMGB1 as well as an antagonist of HMGB1 (Fig. 3).
Thrombomodulin, HMGB1 and Dendritic Cells
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Fig.　3　TM can antagonize the effect of HMGB1 on DCs. The percentage of TM+ DCs derived 
from mouse bone marrow cells was determined by fl ow cytometry and increases when the cells are 
treated with rhTM by itself or anti-HMGB1 by itself, or both rhTM and anti-HMGB1 together, but de-
creases when exogenous HMGB1 is added to the culture medium at day 4 (A). The fi gure is repre-
sentative of three independent experiments. The levels of TNF-α in the DC culture supernatants on 
day 6 were assayed by ELISA (B). Error bars indicate s.d. Statistical analysis by ANOVA with post 
hoc Fisher’s predicted least signifi cant difference test.
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RAGE NOT NEEDED FOR TM INTERACTION
WITH DCs
RAGE is the critical receptor for HMGB1 on DCs
causing their maturation and migration.26,27 If TM
acts solely by antagonizing HMGB1 binding to
RAGE, then it would be predicted that DCs from
RAGE deficient mice would not respond to TM. To
test this prediction, bone marrow cells from RAGE
deficient mice28 were differentiated in the presence of
200 nM rhTM. As in DCs derived from C57BL6 wild
type (WT) mice, differentiation in the presence of TM
led to increased TM expression on DCs from RAGE
deficient mice (Fig. 4A, B). To investigate further the
effects of rhTM treatment on DCs derived from
RAGE deficient mice, the level of the pro-
inflammatory cytokine, TNF-α, in the DC culture me-
dium on day 6 was determined by ELISA. Addition of
rhTM decreases TNF-α, levels in culture medium
with DCs derived from both WT and RAGE deficient
animals (Fig. 4C) showing that the DCs from RAGE
deficient mice as well as wild type mice change func-
tionally upon rhTM treatment. As TM expression
on DCs is still induced by TM treatment of cells that
lack RAGE and therefore do not respond to HMGB1,
this suggests that in this case TM is modulating the
DCs by a different mechanism than antagonism of
HMGB1.
HUMAN MONOCYTE-DERIVED DCs RESPOND
TO TM AND HMGB1
As the human and mouse immune systems have di-
verged in evolution, we investigated if human DCs
also responded in a similar manner to HMGB1 in the
presence or absence of rhTM. As a marker for the ef-
fects of TM on these human monocyte derived DCs
we used the reduction of expression in the DC matu-
ration markers, HLA-DR and CD86 that had been pre-
viously shown to correlate with the changes in the
phenotype of human DCs.21 Similarly to mouse bone
marrow-derived DCs as shown in our recent publica-
tion,21 200 nM rhTM was found to modestly inhibit
the increase in the expression of maturation markers
(HLA-DR, CD86) on human monocyte-derived DCs
(Fig. 5). Addition of 2 μgml HMGB1 enhanced ex-
pression of CD86 while concomitant addition of 200
nM rhTM neutralized that effect. To investigate if
HMGB1 and rhTM treatment affect DC functionality,
the levels of the pro-inflammatory cytokines, IL-12
p70 and TNF-α, in the culture medium on day 6 were
determined by ELISA. Treatment with HMGB1 in-
creases TNF-α IL-12 p70 levels, while rhTM addition
reduces it (Fig. 6). This observation suggests that in
human, as in mouse, TM and HMGB1 are mutually
antagonistic in their effects on DC expression of
maturation markers.
DISCUSSION
The results of this study showed that treatment with
rhTM is capable of inhibiting the secretion and stimu-
latory activity of HMGB1 in DCs. TM affects the
properties of DCs even in the absence of RAGE, the
HMGB1 receptor, that the effect of TM is similar in
both mouse and human DCs. In earlier experiments
TM expressed as the full length molecule including
its transmembrane domain in situ in endothelial cell
membranes as well as soluble TM preparations such
as rhTM had been shown to induce TM on the DC
surface and reduce the levels of DC maturation mark-
Toda M et al.
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Fig.　4　DCs from mice lacking RAGE respond to TM. Bone marrow cells were isolated from WT C57BL/6 and RAGE 
defi cient mice and treated with GM-CSF for 6 days, rhTM was added from days 4 to 6, and on day 7 they were cultured 
overnight in the presence of rhTM before determining TM expression by fl ow cytometry with isotype control in gray (A) 
and the percentage of TM+ DCs calculated (B). Representative results from three independent experiments are shown. 
The levels of TNF-α in the DC culture supernatants on day 6 were assayed by ELISA (C). Error bars indicate s.d. Data 
analyzed by ANOVA with post hoc Fisher’s predicted least signifi cant difference test.
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ers.21 These effects were probably due to the lectin
domain as DCs from mice that have the TM lectin de-
leted do not respond to added rhTM.
Based on the data presented here, TM affects DCs
by both antagonizing HMGB1 and via an independ-
ent mechanism. The lectin domain of TM binds to Le-
wisY,8 a blood group antigen, and is reported to inter-
act directly with cells29 and to antagonize HMGB1.9
Thus TM could interact with DCs by two different
mechanisms: by binding HMGB1 preventing it sig-
naling through RAGE andor by its own yet to be
identified receptor that might contain Lewisy (Fig. 7).
Addition of HMGB1 reduced TM expression on DCs
and increased that of maturation markers suggesting
that HMGB1 and TM were mutually antagonistic.
This was supported by data showing that production
of pro-inflammatory cytokines was reduced in DCs
treated with rhTM but increased in DCs treated with
HMGB1, suggesting that the rhTM treatement af-
fected the functionality of the DCs. Recently we have
shown that there are global changes in gene expres-
sion that occur in mouse DCs upon treatment with
rhTM.30 The mRNA from the genes encoding TNF-α
and IL-12 p70 were amongst those that were down
regulated, in agreement with the data presented
here. The level of HMGB1 mRNA was unchanged in
DCs treated with rhTM suggesting that export of
HMGB1 is higher in control than TM treated DCs.
This reduction in HMGB1 secretion was also found in
sorted TM+ DCs compared to TM− DCs showing that
this property correlates with the induction of toler-
ance.21
Removal of HMGB1 by a neutralizing antibody,
however, did not prevent TM treatment inducing its
own expression. In addition TM treatment still in-
duced higher expression of TM on DCs from mice
lacking RAGE, the receptor for HMGB1, suggesting
that there is an alternative mechanism by which
rhTM is modulating the properties of DCs, possibly
via an unidentified TM receptor. Taken together,
these data indicate that TM is probably influencing
the outcome by both mechanisms, one via antago-
nism of HMGB1 and the other via the postulated re-
ceptor. HMGB1 may not just affect DCs but may also
be required for clonal proliferation of T-cells.10 Thus,
sequestration of HMGB1 by TM would also reduce
Thrombomodulin, HMGB1 and Dendritic Cells
Allergology International Vol 63, No1, 2014 www.jsaweb.jp 63
Fig.　5　TM and HMGB1 modulate human DCs. Human monocytes were differentiated to DCs for 5 days in me-
dium depleted of HMGB1 to which 2 μg/ml of HMGB1 was added with or without rhTM. Expression of maturation 
markers (HLA-DR and CD86) was analyzed by fl ow cytometry with isotype control in gray; untreated DCs in blue 
and rhTM treated DCs in red (A) and the percentage of TM+ DCs calculated (B). Representative results from 
three independent experiments are shown. Error bars indicate s.d. Data analyzed by ANOVA with post hoc Fish-
er’s predicted least signifi cant difference test.
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Fig.　6　TM treatment of human DCs reduces TNF-α while HMGB1 treatment increases it. The lev-
els of TNF-α (A) and IL-12p70 (B) in human DC culture supernatants on day 6 from the experiments 
described in Figure 5 were assayed by ELISA. Error bars indicate s.d. Data analyzed by ANOVA 
with post hoc Fisher’s predicted least signifi cant difference test.
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clonal T-cell responses, consequently lowering in-
flammatory responses.31
Following treatment with rhTM in models of sepsis
and heat stress, plasma levels of HMGB1 are re-
duced.32-34 In addition inflammatory cytokines are
lower and the outcome in the models is beneficial
which is in vivo data consistent with the hypothesis
that TM and HMGB1 are mutually antagonistic.
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Fig.　7　Schematic overview of the responses of DCs to TM. Upon generation, DCs pos-
sess both RAGE and a postulated TM receptor (TMR) on their cell surface. In the ab-
sence of exogenous TM, the DCs secrete HMGB1 causing RAGE signaling and the DCs 
to remain immunogenic (left panel). Added rhTM as well as TM on endothelial cells and 
other DCs can modulate DCs via two mechanisms. Firstly, TM binds to HMGB1 prevent-
ing RAGE signaling also leading to tolerogenic DCs (right panel). Secondly, with TM pres-
ent, the DCs are stimulated via the TMR to induce more TM on their cell surface thereby 
becoming tolerogenic and secreting less HMGB1 (center panel).
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In the lung when a foreign antigen is detected by
DCs, the environment in which the DCs phagocytose
the antigen and migrate to the draining lymph node,
will determine the subsequent behaviour of that DC.
If there has been prior or ongoing inflammation, co-
agulation and infection, HMGB1 will be secreted35
causing the DCs to become immunogenic. In this
scenario, TM can be oxidized, losing its ability to acti-
vate PC,36 be cleaved from the EC cell surface by pro-
teases37 and be down-regulated by inflammatory cy-
tokines.38 Thus the DCs will encounter HMGB1 in
the absence of TM, causing the DCs to become im-
munogenic. Alternatively, in quiescent, non-
inflammatory conditions, the migrating DCs will be
able to interact with intact TM on endothelial cells,
causing induction of tolerance.
In brief, the results of this study show that TM
modulates DCs both by antagonizing the interaction
of HMGB1 with RAGE and by an independent
mechanism. Recently a subset of human DCs expre-
ssing TM has been suggested to be highly active in
actively phagocytosing necrotic cells39 while a role for
TM+ DCs has been suggested in allergy and asthma.40,41
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